Evidence map›Paper›PMID 37769225›Full record

ArticleJCO precision oncology2023

Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors.

Marcia S Brose, David S Hong, Alexander Drilon

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Reply to M.S. Brose et al.JCO precision oncology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Marcia S BroseMarcia S. Brose, MD, PhD, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA; David S. Hong, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-7096-4057
David S HongMarcia S. Brose, MD, PhD, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA; David S. Hong, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Weill Cornell Medical College, New York, NY.
Alexander DrilonMarcia S. Brose, MD, PhD, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA; David S. Hong, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Weill Cornell Medical College, New York, NY.ORCID 0000-0001-6806-9061

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibitionR01CA226864 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DRILON, ALEXANDER, VENTURA, ANDREA · 2018 to 2021
$2.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA226864
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsTropomyosinHumansReceptor Protein-Tyrosine KinasesReceptors, Amino AcidReceptor Protein-Tyrosine KinasesReceptors, Amino AcidTropomyosintyrosine receptor

Identifiers

PMID37769225
PMCPMC10581609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.